Atossa Therapeutics Announces Full Results From Phase 2 KARISMA-Endoxifen Study To Be Presented At 2024 San Antonio Breast Cancer Symposium; Demonstrated Statistically Significant Reductions In Mammographic Breast Density
Atossa Therapeutics Announces Full Results From Phase 2 KARISMA-Endoxifen Study To Be Presented At 2024 San Antonio Breast Cancer Symposium; Demonstrated Statistically Significant Reductions In Mammographic Breast Density
Atossa Therapeutics 宣佈將在2024年聖安東尼奧乳腺癌研討會上展示第二階段KARISMA-Endoxifen研究的完整結果；顯示出乳腺X光攝影密度的統計學顯著降低。
Atossa Therapeutics Announces Full Results From Phase 2 KARISMA-Endoxifen Study To Be Presented At 2024 San Antonio Breast Cancer Symposium; Demonstrated Statistically Significant Reductions In Mammographic Breast Density
Atossa Therapeutics 宣佈將在2024年聖安東尼奧乳腺癌研討會上展示第二階段KARISMA-Endoxifen研究的完整結果；顯示出乳腺X光攝影密度的統計學顯著降低。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。